Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits

 
• By Alexandra Shimmings

Clovis Oncology is forging ahead with a filing for a maintenance indication for its PARP inhibitor Rubraca in a broad ovarian cancer population as new data from ARIEL3 blow the field wide open.

Mermaid
ARIEL seeks a new world of patients for Rubraca • Source: Shutterstock

More from Clinical Trials

More from R&D